Engineered immune cells take on Hard-to-Treat myeloma
NCT ID NCT04795882
First seen Nov 20, 2025 · Last updated Apr 24, 2026 · Updated 13 times
Summary
This early-stage trial tests a new type of CAR T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The therapy uses specially engineered immune cells to target two proteins (BCMA and CD19) on cancer cells. The main goals are to see if the treatment is safe and if the cells can be successfully made for each patient. About 27 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospital
RECRUITINGLondon, County (Optional), United Kingdom
Contact
Conditions
Explore the condition pages connected to this study.